- Target disease: Visceral leishmaniasis
- Main partners (since project start): Takeda Pharmaceutical Company Ltd, Japan
- Project start: March 2018 (for 2 years)
- Funding (since project start): GHIT (Takeda recipient)
This project is the continuation of the optimization of the aminopyrazole series for visceral leishmaniasis project. DNDi and Takeda worked with the objective of delivering an anti-parasitic aminopyrazole drug that could meet the Target Product Profile (TPP) published by DNDi. A lead second generation compound DNDI-5561 and several additional advanced, and differentiated, second generation leads have been identified that could provide differentiated back-ups.
Following positive results of efficacy and safety studies in animal model, DNDI-5561 was selected as pre-clinical candidate.
Last update: April 2018